These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 34297412)
101. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064 [TBL] [Abstract][Full Text] [Related]
102. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052 [TBL] [Abstract][Full Text] [Related]
103. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression. Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179 [TBL] [Abstract][Full Text] [Related]
104. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer. Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761 [TBL] [Abstract][Full Text] [Related]
105. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines. Yang J; Sontag D; Gong Y; Minuk GY Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415 [TBL] [Abstract][Full Text] [Related]
106. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Liu M; Yang J; Zhang Y; Zhou Z; Cui X; Zhang L; Fung KM; Zheng W; Allard FD; Yee EU; Ding K; Wu H; Liang Z; Zheng L; Fernandez-Zapico ME; Li YP; Bronze MS; Morris KT; Postier RG; Houchen CW; Yang J; Li M Clin Cancer Res; 2018 Jul; 24(13):3186-3196. PubMed ID: 29615456 [No Abstract] [Full Text] [Related]
107. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599 [TBL] [Abstract][Full Text] [Related]
108. Long Noncoding RNA CAT104 Promotes Cell Viability, Migration, and Invasion in Gastric Carcinoma Cells Through Activation of MicroRNA-381-Inhibiting Zinc Finger E-box-Binding Homeobox 1 (ZEB1) Expression. Yuan G; Quan J; Dong D; Wang Q Oncol Res; 2018 Aug; 26(7):1037-1046. PubMed ID: 29295724 [TBL] [Abstract][Full Text] [Related]
109. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118 [TBL] [Abstract][Full Text] [Related]
110. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression. Hu S; Xia C; Zou H; Ren W; Liu L; Wang L; Kang Q; He K; Wang T; Zhang X Dig Liver Dis; 2023 Aug; 55(8):1114-1125. PubMed ID: 36586771 [TBL] [Abstract][Full Text] [Related]
111. Intrinsic cancer cell phosphoinositide 3-kinase δ regulates fibrosis and vascular development in cholangiocarcinoma. Bou Malham V; Benzoubir N; Vaquero J; Desterke C; Agnetti J; Song PX; Gonzalez-Sanchez E; Arbelaiz A; Jacques S; Di Valentin E; Rahmouni S; Tan TZ; Samuel D; Thiery JP; Sebagh M; Fouassier L; Gassama-Diagne A Liver Int; 2023 Dec; 43(12):2776-2793. PubMed ID: 37804055 [TBL] [Abstract][Full Text] [Related]
113. ZEB1: Catalyst of immune escape during tumor metastasis. Lu J; Fei F; Wu C; Mei J; Xu J; Lu P Biomed Pharmacother; 2022 Sep; 153():113490. PubMed ID: 36076506 [TBL] [Abstract][Full Text] [Related]
114. E2F transcription factor 1 (E2F1) enhances the proliferation, invasion and EMT of trophoblast cells by binding to Zinc Finger E-Box Binding Homeobox 1 (ZEB1). Gong H; Lu F; Zeng X; Bai Q Bioengineered; 2022 Feb; 13(2):2360-2370. PubMed ID: 35030974 [TBL] [Abstract][Full Text] [Related]
115. ZEB1: New advances in fibrosis and cancer. Cheng L; Zhou MY; Gu YJ; Chen L; Wang Y Mol Cell Biochem; 2021 Apr; 476(4):1643-1650. PubMed ID: 33417164 [TBL] [Abstract][Full Text] [Related]
116. Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy. Burchard PR; Ruffolo LI; Ullman NA; Dale BS; Dave YA; Hilty BK; Ye J; Georger M; Jewell R; Miller C; De Las Casas L; Jarolimek W; Perryman L; Byrne MM; Loria A; Marin C; Chávez Villa M; Yeh JJ; Belt BA; Linehan DC; Hernandez-Alejandro R Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39101793 [TBL] [Abstract][Full Text] [Related]
117. Septin 9 expression regulates 'don't eat me' signals and identifies an immune-epithelial class of intrahepatic cholangiocarcinoma. Cai TT; Desterke C; Peng J; Agnetti J; Song P; Ouazib D; Dos Santos A; Guettier C; Samuel D; Gassama-Diagne A Mol Oncol; 2024 Oct; 18(10):2369-2392. PubMed ID: 39082897 [TBL] [Abstract][Full Text] [Related]
118. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. Raggi C; Fiaccadori K; Pastore M; Correnti M; Piombanti B; Forti E; Navari N; Abbadessa G; Hall T; Destro A; Di Tommaso L; Roncalli M; Meng F; Glaser S; Rovida E; Peraldo-Neia C; Olaizola P; Banales JM; Gerussi A; Elvevi A; Droz Dit Busset M; Bhoori S; Mazzaferro V; Alpini G; Marra F; Invernizzi P Am J Pathol; 2019 Oct; 189(10):2090-2101. PubMed ID: 31351075 [TBL] [Abstract][Full Text] [Related]
119. Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling. Johnson C; Huynh V; Hargrove L; Kennedy L; Graf-Eaton A; Owens J; Trzeciakowski JP; Hodges K; DeMorrow S; Han Y; Wong L; Alpini G; Francis H Am J Pathol; 2016 Jan; 186(1):123-33. PubMed ID: 26597881 [TBL] [Abstract][Full Text] [Related]
120. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma. Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]